You can’t give yourself type 1 diabetes. It’s an autoimmune disease, not something caused by diet, sugar intake, weight, or lifestyle choices. The immune system attacks and destroys the insulin-producing cells in the pancreas, and by the time symptoms appear, at least half of those cells are already gone. What determines whether someone develops type 1 diabetes comes down to genetics, immune system behavior, and possibly environmental triggers that remain only partially understood.
What Actually Causes Type 1 Diabetes
Type 1 diabetes develops when a specific branch of the immune system, the T cells that normally fight infections, mistakenly identifies the insulin-producing beta cells in the pancreas as threats. These immune cells infiltrate the pancreas and systematically destroy beta cells over months or years. The process is silent at first. Based on surgical data, at least 50% of beta cells need to be destroyed before blood sugar rises high enough to cause noticeable symptoms.
This autoimmune destruction isn’t something a person triggers through behavior. It’s fundamentally different from type 2 diabetes, which involves insulin resistance and is closely linked to weight, activity level, and metabolic health. Type 1 can strike anyone, at any age, regardless of how healthy they are.
The Role of Genetics
Certain gene variants dramatically increase the likelihood of developing type 1 diabetes. The most significant are in the HLA region, a set of genes that help the immune system distinguish the body’s own cells from invaders. Two specific combinations, known as HLA-DR3/DQ2 and HLA-DR4/DQ8, carry the highest risk.
The numbers tell the story clearly. In the Diabetes Autoimmunity Study of the Young, siblings who inherited both high-risk HLA types had a 55% chance of developing type 1 diabetes by age 12 and a 63% chance of producing islet cell autoantibodies by age 7. Siblings who shared zero or only one of those gene types had just a 5% risk of the disease by age 12. Genetics loads the gun, but not everyone with high-risk genes develops the disease, which is why researchers have long looked for additional triggers.
Environmental Triggers Under Investigation
Something in the environment appears to set off the autoimmune process in genetically susceptible people, but pinning down exactly what has proven difficult. The leading candidate is viral infection, particularly a group of common viruses called enteroviruses. One strain, coxsackievirus B, has received the most attention. The theory is molecular mimicry: proteins on the surface of certain viruses look structurally similar to proteins on beta cells, confusing the immune system into attacking both.
Research has shown that beta cells infected by coxsackievirus B are killed more effectively by the virus itself than by the immune response to it, which has led to an unexpected strategy. A pharmaceutical company (now part of Sanofi) is developing a vaccine against specific enterovirus strains thought to accelerate type 1 diabetes development. The idea is that preventing the viral infection might prevent the autoimmune cascade from starting.
Vitamin D deficiency has also been proposed as a risk factor, but a large genetic analysis published in PLOS Medicine found that lower vitamin D levels did not have a substantial impact on type 1 diabetes risk. The researchers noted they couldn’t rule out effects of vitamin D exposure during pregnancy, but the evidence does not support raising vitamin D levels as a prevention strategy for type 1 diabetes.
How the Disease Is Staged
Type 1 diabetes doesn’t appear overnight. It progresses through three recognized stages, a framework established jointly by the Juvenile Diabetes Research Foundation, the Endocrine Society, and the American Diabetes Association.
- Stage 1: Two or more autoantibodies are detectable in the blood, but blood sugar is still normal. The immune attack has started, but enough beta cells remain functional.
- Stage 2: Autoantibodies are present and blood sugar is starting to become abnormal, though full diabetes hasn’t developed yet. Beta cell loss is progressing.
- Stage 3: Clinical diabetes with obvious symptoms. This is where most people are diagnosed.
Four autoantibodies serve as the key warning markers: antibodies against insulin, against an enzyme called GAD65, against a protein called IA-2, and against a zinc transporter called ZnT8. Between 80% and 90% of children already have detectable autoantibodies at the time they’re diagnosed with type 1 diabetes. The number of autoantibodies matters enormously for prediction. Children with a single autoantibody have a 12.7% risk of developing type 1 diabetes by age 15. With two autoantibodies, that jumps to 61.6%. With three, it reaches 79.1%. Nearly all individuals with multiple autoantibodies will eventually develop clinical type 1 diabetes given enough time.
Symptoms When It Finally Appears
By stage 3, the body can no longer produce enough insulin to manage blood sugar. The classic early symptoms are intense thirst and frequent urination, because the kidneys are trying to flush out excess glucose. These can escalate quickly into a dangerous condition called diabetic ketoacidosis (DKA), where the body starts breaking down fat for energy and produces acidic compounds called ketones.
Signs of DKA include fast, deep breathing, fruity-smelling breath, nausea and vomiting, stomach pain, extreme fatigue, and dry skin. Blood sugar levels in DKA typically climb above 250 to 300 mg/dL. This is a medical emergency. In children especially, DKA is sometimes the very first indication that type 1 diabetes is present, because the earlier stages went undetected.
Adult-Onset Type 1 Diabetes
Type 1 diabetes is often thought of as a childhood disease, but it can develop in adults too. When it appears after age 30 with a slower progression, it’s sometimes called latent autoimmune diabetes in adults, or LADA. The same autoimmune destruction is happening, just at a slower pace. People with LADA typically don’t need insulin right away. They retain some insulin production for months or even years after diagnosis, a longer version of the “honeymoon period” that some children experience briefly after their diagnosis.
LADA is frequently misdiagnosed as type 2 diabetes because of the patient’s age and the initially mild presentation. The distinction matters because treatment strategies differ. LADA is identified through the same autoantibody tests used for childhood type 1 diabetes, particularly GAD65 antibodies.
Can Type 1 Diabetes Be Prevented or Delayed?
There is currently no way to prevent type 1 diabetes. But for the first time, there is a way to delay it. In 2022, the FDA approved teplizumab, an immune-modulating therapy, for people at stage 2 who are at high risk of progressing to clinical disease. In the trial that led to its approval, a single 14-day course of treatment delayed the onset of stage 3 type 1 diabetes by a median of about two years. An updated analysis extended that median delay to roughly 32 and a half months.
The trial was small, with 76 total participants, but the results were significant enough to earn regulatory approval. Teplizumab works by calming down the specific immune cells responsible for destroying beta cells, essentially slowing the attack. It doesn’t cure the underlying autoimmunity, and most treated individuals still eventually progress to clinical diabetes. But those additional months or years without the disease, particularly for children, represent meaningful time.
Screening family members of people with type 1 diabetes through autoantibody blood tests can identify individuals in the early stages before symptoms develop. About 70% of people with two or more autoantibodies progress to clinical type 1 diabetes within 10 years, which makes early detection a practical tool for monitoring and, now, for potentially intervening with therapies like teplizumab.